COVID-19 vaccines and global stock markets

Global stock markets react positively when different phases of human clinical trials on COVID-19 vaccines begin. The average abnormal stock return on the first day of the trials is both statistically and economically significant at 8.08 basis points. The increase in the average abnormal stock return...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Kam Fong, Chen, Zhuo, Wen, Yuanji, Xu, Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898767/
https://www.ncbi.nlm.nih.gov/pubmed/35283695
http://dx.doi.org/10.1016/j.frl.2022.102774
_version_ 1784663733609431040
author Chan, Kam Fong
Chen, Zhuo
Wen, Yuanji
Xu, Tong
author_facet Chan, Kam Fong
Chen, Zhuo
Wen, Yuanji
Xu, Tong
author_sort Chan, Kam Fong
collection PubMed
description Global stock markets react positively when different phases of human clinical trials on COVID-19 vaccines begin. The average abnormal stock return on the first day of the trials is both statistically and economically significant at 8.08 basis points. The increase in the average abnormal stock return is threefold higher for leading vaccine candidates. The positive reaction is more pronounced upon the start of phase III trials, and it is also stronger for vaccine candidates developed by the U.S. and China.
format Online
Article
Text
id pubmed-8898767
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-88987672022-03-07 COVID-19 vaccines and global stock markets Chan, Kam Fong Chen, Zhuo Wen, Yuanji Xu, Tong Financ Res Lett Article Global stock markets react positively when different phases of human clinical trials on COVID-19 vaccines begin. The average abnormal stock return on the first day of the trials is both statistically and economically significant at 8.08 basis points. The increase in the average abnormal stock return is threefold higher for leading vaccine candidates. The positive reaction is more pronounced upon the start of phase III trials, and it is also stronger for vaccine candidates developed by the U.S. and China. Published by Elsevier Inc. 2022-06 2022-03-07 /pmc/articles/PMC8898767/ /pubmed/35283695 http://dx.doi.org/10.1016/j.frl.2022.102774 Text en © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Chan, Kam Fong
Chen, Zhuo
Wen, Yuanji
Xu, Tong
COVID-19 vaccines and global stock markets
title COVID-19 vaccines and global stock markets
title_full COVID-19 vaccines and global stock markets
title_fullStr COVID-19 vaccines and global stock markets
title_full_unstemmed COVID-19 vaccines and global stock markets
title_short COVID-19 vaccines and global stock markets
title_sort covid-19 vaccines and global stock markets
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898767/
https://www.ncbi.nlm.nih.gov/pubmed/35283695
http://dx.doi.org/10.1016/j.frl.2022.102774
work_keys_str_mv AT chankamfong covid19vaccinesandglobalstockmarkets
AT chenzhuo covid19vaccinesandglobalstockmarkets
AT wenyuanji covid19vaccinesandglobalstockmarkets
AT xutong covid19vaccinesandglobalstockmarkets

Ejemplares similares